Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis - A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis -

Trial Profile

Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis - A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis -

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Dexlansoprazole (Primary) ; Lansoprazole
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 03 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top